If it works in rGBM to the tune of 14-15 months OS, I believe, as ludicrous it sound from today's pricing, our market cap would be in the 5-10 billion dollar range, since the implications of the drug utility would be clear for other indications... 200-400 per share upside. It would also be a transformative news story, i.e. extending life by several months in rGBM.
If it doesn't work, maybe 20-40 cents a share.
I don't think they will do the thyroid randomized trial by themselves, but it's possible. Reason: it takes too long... the thyroid tumors grow and, more important for trial design, progress rather slowly. It would take 3-4 years to do a thyroid trial, tough too stomach for VBLT IMHO.
BTW, on the subject of thyroid, I would guess the results will come out in December since thats when the major thyroid meeting is.... around the 1's of December if I recall correctly.
News 
Market Data 
Discover 
